Arbaclofen: all 21 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With thRecruitingNCT07655115Phase 3
- A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple SclerosisNot yet recruitingNCT05179577Phase 3
- A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MSCompletedNCT03319732Phase 3Results posted
- A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MSCompletedNCT03290131Phase 3Results posted
- MEG Study of Acute STX209 Effects in ASDCompletedNCT02278328Early Phase 1Results posted
- Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum DisordersCompletedNCT00846547Phase 2Results posted
- Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X SyndromeCompletedNCT00788073Phase 2Results posted
- Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 DeletionActive, not recruitingNCT04271332Phase 2
- Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA)CompletedNCT03887676Phase 2
- Arbaclofen in Children and Adolescents With ASDCompletedNCT03682978Phase 2
- To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MSWithdrawnNCT02869425Phase 3
- One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With SpasticityCompletedNCT01844232Phase 3
- Efficacy Study of Arbaclofen to Treat Spasticity in Multiple SclerosisCompletedNCT01743651Phase 3
- Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum DisordersTerminatedNCT01706523Phase 3
- An Open Label Extension Study in Subjects With Fragile X SyndromeTerminatedNCT01555333Phase 3
- Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X SyndromeCompletedNCT01325220Phase 3
- Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum DisordersCompletedNCT01288716Phase 2
- Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X SyndromeCompletedNCT01282268Phase 3
- TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal VolunteersTerminatedNCT01172509Phase 1
- An Open Label Extension Study of STX209 in Subjects With Autism Spectrum DisordersTerminatedNCT01064973Phase 2
- An Open Label Extension Study of STX209 in Subjects With Fragile X SyndromeTerminatedNCT01013480Phase 2